Chinese authorities included the dextromethorphan hydrochloride sustained-release capsules manufactured by China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Henan Zhongshuai Pharmaceutical in the country's national insurance drug catalog.
The drug is used as a psychostimulant for attention deficit hyperactivity disorder and nodular disorders in children aged 6 and above, according to a Tuesday filing with the Shanghai bourse.